These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 24507813)

  • 21. 5q- syndrome.
    Boultwood J; Pellagatti A; Wainscoat JS
    Curr Pharm Des; 2012; 18(22):3180-3. PubMed ID: 22571696
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide.
    Jonasova A; Bokorova R; Polak J; Vostry M; Kostecka A; Hajkova H; Neuwirtova R; Siskova M; Sponerova D; Cermak J; Mikulenkova D; Cervinek L; Brezinova J; Michalova K; Fuchs O
    Eur J Haematol; 2015 Jul; 95(1):27-34. PubMed ID: 25284710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of 5q in myeloid malignancies - A gain in understanding of biological and clinical consequences.
    Venugopal S; Mascarenhas J; Steensma DP
    Blood Rev; 2021 Mar; 46():100735. PubMed ID: 32736878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria.
    Aschauer G; Greil R; Linkesch W; Nösslinger T; Stauder R; Burgstaller S; Fiegl M; Fridrik M; Girschikofsky M; Keil F; Petzer A
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e143-9. PubMed ID: 26422252
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome.
    Kumar MS; Narla A; Nonami A; Mullally A; Dimitrova N; Ball B; McAuley JR; Poveromo L; Kutok JL; Galili N; Raza A; Attar E; Gilliland DG; Jacks T; Ebert BL
    Blood; 2011 Oct; 118(17):4666-73. PubMed ID: 21873545
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rps14, Csnk1a1 and miRNA145/miRNA146a deficiency cooperate in the clinical phenotype and activation of the innate immune system in the 5q- syndrome.
    Ribezzo F; Snoeren IAM; Ziegler S; Stoelben J; Olofsen PA; Henic A; Ferreira MV; Chen S; Stalmann USA; Buesche G; Hoogenboezem RM; Kramann R; Platzbecker U; Raaijmakers MHGP; Ebert BL; Schneider RK
    Leukemia; 2019 Jul; 33(7):1759-1772. PubMed ID: 30651631
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
    Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
    Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.
    Haferlach C; Bacher U; Tiu R; Maciejewski JP; List A
    Cancer Genet Cytogenet; 2008 Dec; 187(2):101-11. PubMed ID: 19027491
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evolution of severe (transfusion-dependent) anaemia in myelodysplastic syndromes with 5q deletion is characterized by a macrophage-associated failure of the eythropoietic niche.
    Buesche G; Teoman H; Schneider RK; Ribezzo F; Ebert BL; Giagounidis A; Göhring G; Schlegelberger B; Bock O; Ganser A; Aul C; Germing U; Kreipe H
    Br J Haematol; 2022 Jul; 198(1):114-130. PubMed ID: 35362549
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis.
    Matsuoka A; Tochigi A; Kishimoto M; Nakahara T; Kondo T; Tsujioka T; Tasaka T; Tohyama Y; Tohyama K
    Leukemia; 2010 Apr; 24(4):748-55. PubMed ID: 20130600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients.
    Caceres G; McGraw K; Yip BH; Pellagatti A; Johnson J; Zhang L; Liu K; Zhang LM; Fulp WJ; Lee JH; Al Ali NH; Basiorka A; Smith LJ; Daugherty FJ; Littleton N; Wells RA; Sokol L; Wei S; Komrokji RS; Boultwood J; List AF
    Proc Natl Acad Sci U S A; 2013 Oct; 110(40):16127-32. PubMed ID: 24043769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of lenalidomide in the management of myelodysplasia with del 5q.
    Kelaidi C; Eclache V; Fenaux P
    Br J Haematol; 2008 Feb; 140(3):267-78. PubMed ID: 18217896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes.
    List A
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S302-4. PubMed ID: 19778857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies.
    Giagounidis AA; Germing U; Aul C
    Clin Cancer Res; 2006 Jan; 12(1):5-10. PubMed ID: 16397017
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of lenalidomide treatment and complete cytogenetic remission in a case of myelodysplastic syndrome with del(5q) and del(9q).
    Xiong B; Liu X; Zou P; Fan L; Chen W; Li W; Liu L
    Leuk Res; 2010 Jul; 34(7):e169-72. PubMed ID: 20122730
    [No Abstract]   [Full Text] [Related]  

  • 36. Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?
    Vozella F; Latagliata R; Carmosino I; Volpicelli P; Montagna C; Romano A; Roberto A; Finsinger P; Mancini M; Breccia M; Oliva E; Oliva E
    Hematol Oncol; 2015 Mar; 33(1):48-51. PubMed ID: 25950027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Persistent malignant stem cells in del(5q) myelodysplasia in remission.
    Tehranchi R; Woll PS; Anderson K; Buza-Vidas N; Mizukami T; Mead AJ; Astrand-Grundström I; Strömbeck B; Horvat A; Ferry H; Dhanda RS; Hast R; Rydén T; Vyas P; Göhring G; Schlegelberger B; Johansson B; Hellström-Lindberg E; List A; Nilsson L; Jacobsen SE
    N Engl J Med; 2010 Sep; 363(11):1025-37. PubMed ID: 20825315
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells.
    Dutt S; Narla A; Lin K; Mullally A; Abayasekara N; Megerdichian C; Wilson FH; Currie T; Khanna-Gupta A; Berliner N; Kutok JL; Ebert BL
    Blood; 2011 Mar; 117(9):2567-76. PubMed ID: 21068437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide.
    Wei S; Chen X; Rocha K; Epling-Burnette PK; Djeu JY; Liu Q; Byrd J; Sokol L; Lawrence N; Pireddu R; Dewald G; Williams A; Maciejewski J; List A
    Proc Natl Acad Sci U S A; 2009 Aug; 106(31):12974-9. PubMed ID: 19470455
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion.
    Cannella L; Latagliata R; Breccia M; Carmosino I; Loglisci G; Volpicelli P; Ferretti A; Santopietro M; Vozella F; Girmenia C; Cuzzola M; Oliva EN; Alimena G
    Ann Hematol; 2012 Feb; 91(2):309-10. PubMed ID: 21625998
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.